5-Amino-1MQ

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NOT a peptide. Animal studies suggest it may increase NAD+ levels and promote fat loss, but human data is lacking.

PubMed results: 0 · Human studies: 0 · Animal studies: 0

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Oral — standard range No established dosing, Not established. Animal research has used oral NNMT-inhibitor regimens in mice; absolute mg/kg figures vary by study design and are not transferable to a validated human protocol. No completed human PK or dose-ranging studies establish a clinical range.

Not established in humans (theoretical confidence)

Small-molecule NNMT inhibitor; no published human PK. Preclinical literature does not report a validated plasma half-life for 5-Amino-1MQ.

• NNMT inhibition and NAD+ support (Strong preclinical): Animal and cell studies indicate that 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), a pathway linked to elevated NAD+ availability and altered cellular energy metabolism.
• Adipose tissue and body composition research (Limited): Preclinical models suggest NNMT inhibition may reduce fat mass accumulation and influence lipid handling; published human efficacy data remain sparse.
• Metabolic signaling modulation (Theoretical): Research frames 5-Amino-1MQ as a small-molecule probe of NNMT-dependent methyl transfer and NAD salvage pathways rather than a clinically established metabolic agent.

• No well-characterized human safety profile — Mild, Not established. Human clinical safety data for 5-Amino-1MQ are largely absent from peer-reviewed literature; adverse-effect frequency and severity have not been established in controlled trials.

• Pregnancy and lactation (Theoretical / Preclinical): Absence of reproductive toxicology and human exposure data supports theoretical caution in pregnancy and lactation research contexts.
• Uncharacterized metabolic disease contexts (Theoretical / Preclinical): NNMT and NAD pathway modulation could interact with poorly studied metabolic states; evidence for clinical contraindications is theoretical.

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

No PubMed-indexed primary literature was found for this compound at review time. Sections summarize commonly cited research context; treat as lower-confidence until citations are added.